Literature DB >> 32682948

Anaerobic Antibiotics and the Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

John S Tanaka1, Rebecca R Young2, Sarah M Heston2, Kirsten Jenkins2, Lisa P Spees3, Anthony D Sung4, Kelly Corbet4, Jillian C Thompson4, Lauren Bohannon4, Paul L Martin5, Andre Stokhuyzen5, Richard Vinesett5, Doyle V Ward6, Shakti K Bhattarai7, Vanni Bucci7, Mehreen Arshad8, Patrick C Seed8, Matthew S Kelly9.   

Abstract

Certain anaerobic bacteria are important for maintenance of gut barrier integrity and immune tolerance and may influence the risk of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a single-center retrospective cohort study of allogeneic HSCT recipients to evaluate associations between receipt of antibiotics with an anaerobic spectrum of activity and GVHD outcomes. We identified 1214 children and adults who developed febrile neutropenia between 7 days before and 28 days after HSCT and compared GVHD risk and mortality among patients who received anaerobic antibiotics (piperacillin-tazobactam or carbapenems; n = 491) to patients who received only antibiotics with minimal activity against anaerobes (aztreonam, cefepime, or ceftazidime; n = 723). We performed metagenomic sequencing of serial fecal samples from 36 pediatric patients to compare the effects of specific antibiotics on the gut metagenome. Receipt of anaerobic antibiotics was associated with higher hazards of acute gut/liver GVHD (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.03 to 1.54) and acute GVHD mortality (HR, 1.63; 95% CI, 1.08 to 2.46), but not chronic GVHD diagnosis (HR, 1.04; 95% CI: .84 to 1.28) or chronic GVHD mortality (HR, .88; 95% CI, .53 to 1.45). Anaerobic antibiotics resulted in decreased gut bacterial diversity, reduced abundances of Bifidobacteriales and Clostridiales, and loss of bacterial genes encoding butyrate biosynthesis enzymes from the gut metagenome. Acute gut/liver GVHD was preceded by a sharp decline in bacterial butyrate biosynthesis genes with antibiotic treatment. Our findings demonstrate that exposure to anaerobic antibiotics is associated with increased risks of acute gut/liver GVHD and acute GVHD mortality after allogeneic HSCT. Use of piperacillin-tazobactam or carbapenems should be reserved for febrile neutropenia cases in which anaerobic or multidrug-resistant infections are suspected.
Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carbapenems; Febrile neutropenia; Gut microbiome; Piperacillin-tazobactam

Mesh:

Substances:

Year:  2020        PMID: 32682948      PMCID: PMC7609492          DOI: 10.1016/j.bbmt.2020.07.011

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  38 in total

Review 1.  Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host.

Authors:  Vadivel Ganapathy; Muthusamy Thangaraju; Puttur D Prasad; Pamela M Martin; Nagendra Singh
Journal:  Curr Opin Pharmacol       Date:  2013-08-23       Impact factor: 5.547

2.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

3.  Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies.

Authors:  H Celebi; H Akan; E Akçağlayan; C Ustün; M Arat
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

4.  Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.

Authors:  John M Magenau; Xuemei Qin; Isao Tawara; Clare E Rogers; Carrie Kitko; Matthew Schlough; Daniel Bickley; Thomas M Braun; Pil-Sang Jang; Kathleen P Lowler; Dawn M Jones; Sung W Choi; Pavan Reddy; Shin Mineishi; John E Levine; James L M Ferrara; Sophie Paczesny
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-17       Impact factor: 5.742

5.  Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation.

Authors:  Daniela Weber; Robert R Jenq; Jonathan U Peled; Ying Taur; Andreas Hiergeist; Josef Koestler; Katja Dettmer; Markus Weber; Daniel Wolff; Joachim Hahn; Eric G Pamer; Wolfgang Herr; André Gessner; Peter J Oefner; Marcel R M van den Brink; Ernst Holler
Journal:  Biol Blood Marrow Transplant       Date:  2017-02-14       Impact factor: 5.742

6.  Variable responses of human microbiomes to dietary supplementation with resistant starch.

Authors:  A Venkataraman; J R Sieber; A W Schmidt; C Waldron; K R Theis; T M Schmidt
Journal:  Microbiome       Date:  2016-06-29       Impact factor: 14.650

7.  Clinical Metabolomics Identifies Blood Serum Branched Chain Amino Acids as Potential Predictive Biomarkers for Chronic Graft vs. Host Disease.

Authors:  Marcos Rodrigo Alborghetti; Maria Elvira Pizzigatti Correa; Jennifer Whangbo; Xu Shi; Juliana Aparecida Aricetti; Andreia Aparecida da Silva; Eliana Cristina Martins Miranda; Mauricio Luis Sforca; Camila Caldana; Robert E Gerszten; Jerome Ritz; Ana Carolina de Mattos Zeri
Journal:  Front Oncol       Date:  2019-03-18       Impact factor: 6.244

8.  Trimmomatic: a flexible trimmer for Illumina sequence data.

Authors:  Anthony M Bolger; Marc Lohse; Bjoern Usadel
Journal:  Bioinformatics       Date:  2014-04-01       Impact factor: 6.937

Review 9.  Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut.

Authors:  Audrey Rivière; Marija Selak; David Lantin; Frédéric Leroy; Luc De Vuyst
Journal:  Front Microbiol       Date:  2016-06-28       Impact factor: 5.640

10.  Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity.

Authors:  Annelies Geirnaert; Marta Calatayud; Charlotte Grootaert; Debby Laukens; Sarah Devriese; Guy Smagghe; Martine De Vos; Nico Boon; Tom Van de Wiele
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

View more
  6 in total

1.  Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation.

Authors:  Caitlin W Elgarten; Ceylan Tanes; Jung-Jin Lee; Lara A Danziger-Isakov; Michael S Grimley; Michael Green; Marian G Michaels; Jessie L Barnum; Monica I Ardura; Jeffery J Auletta; Jesse Blumenstock; Alix E Seif; Kyle L Bittinger; Brian T Fisher
Journal:  Pediatr Blood Cancer       Date:  2021-10-28       Impact factor: 3.167

2.  Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease

Authors:  Caitlin W Elgarten; Yimei Li; Kelly D Getz; Michael Hemmer; Yuan-Shung V Huang; Matthew Hall; Tao Wang; Carrie L Kitko; Madan H Jagasia; Taiga Nishihori; Hemant S Murthy; Hasan Hashem; Mitchell S Cairo; Akshay Sharma; Shahrukh K Hashmi; Medhat Askar; Amer Beitinjaneh; Matthew S Kelly; Jeffery J Auletta; Sherif M Badawy; Melissa Mavers; Richard Aplenc; Margaret L MacMillan; Stephen R Spellman; Mukta Arora; Brian T Fisher
Journal:  Transplant Cell Ther       Date:  2020-12-21

Review 3.  The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.

Authors:  Sarah A Holstein; Nizar Bahlis; P Leif Bergsagel; Manisha Bhutani; Niccolo Bolli; Carrie Brownstein; Pierre Demolis; David Foureau; Francesca Gay; Irene M Ghobrial; Nicole Gormley; Jens Hillengass; Martin Kaiser; Marcela V Maus; J Joseph Melenhorst; Maximilian Merz; Michael O Dwyer; Bruno Paiva; Marcelo C Pasquini; Nina Shah; Sandy W Wong; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2021-06-06

4.  Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy.

Authors:  Jose F Camargo; Maria A Mendoza; Rick Lin; Ilona V Moroz; Anthony D Anderson; Michelle I Morris; Yoichiro Natori; Akina Natori; Mohammed Raja; Lazaros Lekakis; Amer Beitinjaneh; Antonio Jimenez; Mark Goodman; Trent Wang; Krishna V Komanduri; Denise Pereira
Journal:  Transpl Infect Dis       Date:  2021-05-02

Review 5.  Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia.

Authors:  Matthias Wölfl; Muna Qayed; Maria Isabel Benitez Carabante; Tomas Sykora; Halvard Bonig; Anita Lawitschka; Cristina Diaz-de-Heredia
Journal:  Front Pediatr       Date:  2022-01-06       Impact factor: 3.418

6.  Dietary manipulation of the gut microbiome in inflammatory bowel disease patients: Pilot study.

Authors:  Barbara Olendzki; Vanni Bucci; Caitlin Cawley; Rene Maserati; Margaret McManus; Effie Olednzki; Camilla Madziar; David Chiang; Doyle V Ward; Randall Pellish; Christine Foley; Shakti Bhattarai; Beth A McCormick; Ana Maldonado-Contreras
Journal:  Gut Microbes       Date:  2022 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.